The bill proposes the enactment of section 3902.65 of the Revised Code, which aims to cap cost-sharing for prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices. It defines key terms such as "prescription insulin drug," "diabetes device," and "diabetic ketoacidosis device," establishing a framework for what constitutes these items. The bill stipulates that health plan issuers cannot require cost-sharing that exceeds $35 for a thirty-day supply of prescription insulin drugs and $100 for a thirty-day supply of diabetes devices or diabetic ketoacidosis devices.

Additionally, the bill clarifies that these cost-sharing limitations apply regardless of any other cost-sharing requirements that may typically apply under a health benefit plan. It also allows health plan issuers the flexibility to reduce cost-sharing amounts below the specified caps if they choose to do so. This legislation is designed to alleviate the financial burden on individuals requiring these essential medical supplies and medications.